AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9025120 — intervention group
Group type: COMPARATOR
Intervention: Biological parents of comparison boys
Number of subjects: 27
Study 7952304 — intervention group
Group type: EXPERIMENTAL
Intervention: New prosthetic heart valves
Number of subjects: 800
Study 7952304 — intervention group
Group type: COMPARATOR
Intervention: Currently marketed replacement heart valves
Number of subjects: 800
Study 3414992 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine (15 mg)
Number of subjects: 40
Study 3414992 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (15 mg)
Number of subjects: 40
Study 31810393 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 117
Study 31810393 — intervention group
Group type: COMPARATOR
Intervention: Dimenhydrinate
Number of subjects: 117
Study 31810393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 29649764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal progesterone (9 mg MPP22)
Number of subjects: 12
Study 29649764 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 12
Study 29649764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal progesterone (4.5 mg MPP22)
Number of subjects: 12
Study 29649764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28766132 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1396
Study 28766132 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 1396
Study 28766132 — intervention group
Group type: EXPERIMENTAL
Intervention: High AIB1 expression
Number of subjects: 1396
Study 26269564 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 975
Study 26269564 — intervention group
Group type: COMPARATOR
Intervention: Finasteride arm
Number of subjects: 975
Study 23613962 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (CARV)
Number of subjects: 22
Study 23613962 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (CARV) after saline infusion
Number of subjects: 22
Study 23613962 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol (BISOPR)
Number of subjects: 22
Study 20598969 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis combined with enoxaparin, clopidogrel, and aspirin, followed by cardiac catheterization within 6 to 24 hours or rescue coronary intervention if reperfusion fails within 90 minutes of fibrinolysis
Number of subjects: 0
Study 20598969 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI performed according to local guidelines
Number of subjects: 0
Study 20598969 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis combined with enoxaparin, clopidogrel, and aspirin
Number of subjects: 0
Study 20598969 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 0
Study 20598969 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 0
Study 18452763 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 30
Study 18452763 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 30
Study 18452763 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 30
Study 18452763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16643559 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (25 mg daily increment over 1 week to 50 mg for 2 months)
Number of subjects: 64
Study 16643559 — intervention group
Group type: COMPARATOR
Intervention: Sodium valporate (200 mg daily increment over 1 week to 400 mg for 2 months)
Number of subjects: 64
Study 12600850 — intervention group
Group type: COMPARATOR
Intervention: Butter meal (100 g)
Number of subjects: 12
Study 12600850 — intervention group
Group type: COMPARATOR
Intervention: Olive oil meal (80 g)
Number of subjects: 12
Study 12600850 — intervention group
Group type: COMPARATOR
Intervention: Control meal (energy-free soup with 50 g carbohydrate)
Number of subjects: 12
Study 11268452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (5 x 20 mg/m2) over 5 days
Number of subjects: 52
Study 11268452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (1 x 50 mg/m2) plus ifosfamide (4 g/m2) as a single-day infusion
Number of subjects: 52
Study 11268452 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with carboplatin (3 x 500 mg/m2) and ifosfamide (3 x 4 g/m2) over three days
Number of subjects: 52
Study 8752238 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin augmentation
Number of subjects: 197
Study 8752238 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention (awaiting spontaneous labor)
Number of subjects: 197
Study 1373064 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine (1 g orally three times a day for 24 weeks)
Number of subjects: 642
Study 1373064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study 1373064 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 642
Study 1373064 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine and Placebo
Number of subjects: 642
Study 6397652 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF)
Number of subjects: 102
Study 6397652 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study 31486068 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of hearing aids (HAs)
Number of subjects: 114862
Study 29096522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine by infusion
Number of subjects: 102
Study 29096522 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 102
Study 29096522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 102
Study 29096522 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 102
Study 29096522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 26946613 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy plus compound Kushen injection
Number of subjects: 60
Study 26946613 — intervention group
Group type: COMPARATOR
Intervention: Only radiochemotherapy (Control)
Number of subjects: 60
Study 25196631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 63
Study 25196631 — intervention group
Group type: COMPARATOR
Intervention: Medication (ketoprofen tablet thiocolchicoside capsule 2 × 1 for 7 days)
Number of subjects: 63
Study 22432105 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy initiated in 855 patients
Number of subjects: 4900
Study 22432105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonintervention arm)
Number of subjects: 4900
Study 19022418 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive flywheel exercise (FW)
Number of subjects: 25
Study 19022418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg i.v.)
Number of subjects: 25
Study 19022418 — intervention group
Group type: COMPARATOR
Intervention: Bed rest only (Ctrl)
Number of subjects: 25
Study 17761409 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid and docosahexaenoic acid supplementation
Number of subjects: 7
Study 17761409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 15115904 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (carvedilol + enalapril)
Number of subjects: 572
Study 15115904 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 572
Study 15115904 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 572
Study 12239447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine (VBL) 0.15 mg/kg i.v. every 2 weeks and Interferon-gamma (IFN-gamma) 100 microg s.c. 3 times weekly (Trial 1)
Number of subjects: 69
Study 12239447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine (VBL) 0.15 mg/kg i.v. every 2 weeks, Interferon-gamma (IFN-gamma) 100 microg s.c. 3 times weekly, and oral 13-cis retinoic acid (13-CRA) 40 mg/day (Trial 2)
Number of subjects: 69
Study 9846584 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Pro(7) polymorphism in NPY
Number of subjects: 0
Study 9846584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro(7) polymorphism in NPY
Number of subjects: 0
Study 9846584 — intervention group
Group type: COMPARATOR
Intervention: Leu(7)/Leu(7) polymorphism in NPY
Number of subjects: 0
Study 9846584 — intervention group
Group type: COMPARATOR
Intervention: NPY polymorphism
Number of subjects: 0
Study 8031029 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin daily
Number of subjects: 24
Study 8031029 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of ofloxacin daily
Number of subjects: 24
Study 8031029 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ofloxacin, 100 mg of dapsone, and 50 mg of clofazimine daily plus 300 mg of clofazimine once every 28 days
Number of subjects: 24
Study 8031029 — intervention group
Group type: COMPARATOR
Intervention: All groups (400 mg of ofloxacin daily, 800 mg of ofloxacin daily, and combination therapy)
Number of subjects: 24
Study 2648691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of 200 mg Buflomedil
Number of subjects: 42
Study 2648691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 200 mg Buflomedil
Number of subjects: 42
Study 29242238 — intervention group
Group type: EXPERIMENTAL
Intervention: Short telomere length (TL) in leukocytes (LTL)
Number of subjects: 259
Study 29242238 — intervention group
Group type: COMPARATOR
Intervention: Muscle telomere length adjusted for biopsy site (MTLA)
Number of subjects: 259
Study 29242238 — intervention group
Group type: EXPERIMENTAL
Intervention: TL gap between leukocytes and muscle (LTL-MTLA)
Number of subjects: 259
Study 29242238 — intervention group
Group type: EXPERIMENTAL
Intervention: TL ratio between leukocytes and muscle (LTL/MTLA)
Number of subjects: 259
Study 26790833 — intervention group
Group type: EXPERIMENTAL
Intervention: Subinguinal approach
Number of subjects: 81
Study 26790833 — intervention group
Group type: EXPERIMENTAL
Intervention: High inguinal approach
Number of subjects: 81
Study 24648482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IV)
Number of subjects: 72
Study 24648482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine administration (IP)
Number of subjects: 72
Study 24648482 — intervention group
Group type: COMPARATOR
Intervention: Control (IP and IV saline)
Number of subjects: 72
Study 22104642 — intervention group
Group type: EXPERIMENTAL
Intervention: +3.00 D IOL
Number of subjects: 20
Study 22104642 — intervention group
Group type: COMPARATOR
Intervention: +4.00 D IOL
Number of subjects: 20
Study 21309442 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized alpha bandwidths (broad and narrow sub-bands)
Number of subjects: 34
Study 21309442 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use in MDD group
Number of subjects: 34
Study 21309442 — intervention group
Group type: COMPARATOR
Intervention: Traditional fixed 8-13 Hz alpha band
Number of subjects: 34
Study 18678846 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) screening
Number of subjects: 0
Study 16316485 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 30
Study 16316485 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 30
Study 14687444 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg once daily
Number of subjects: 516
Study 14687444 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg three times daily
Number of subjects: 516
Study 11908375 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Actibrush (battery-powered toothbrush)
Number of subjects: 62
Study 11908375 — intervention group
Group type: COMPARATOR
Intervention: Colgate Plus Diamond Head (manual toothbrush)
Number of subjects: 62
Study 8960727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 3,4 diaminopyridine (DAP) up to 100 mg/day
Number of subjects: 36
Study 8960727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 3,4 diaminopyridine (DAP)
Number of subjects: 36
Study 8960727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1561829 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-product influenza vaccine in previously unimmunized full-term children
Number of subjects: 63
Study 1561829 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-product influenza vaccine in sick and recovered reimmunized children
Number of subjects: 63
Study 1561829 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-product influenza vaccine in both cohorts
Number of subjects: 63
Study 1561829 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-product influenza vaccine in full-term children
Number of subjects: 63
Study 4014870 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 ppm O3
Number of subjects: 20
Study 4014870 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 ppm O3
Number of subjects: 20
Study 4014870 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 ppm O3
Number of subjects: 20
Study 4014870 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ppm O3
Number of subjects: 20
Study 4014870 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent heavy exercise (VE, 68 L/min) lasting 14 min every 30 min during exposure
Number of subjects: 20
Study 4014870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough, nose and throat irritation, and chest discomfort
Number of subjects: 20
Study 30366845 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy trials with funding, conducted in Europe and Oceania, and with a Physiotherapy Evidence Database score of at least 6/10
Number of subjects: 200
Study 30366845 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy trials
Number of subjects: 200
Study 28709680 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-CAM laser-sintered RPDs
Number of subjects: 12
Study 28709680 — intervention group
Group type: COMPARATOR
Intervention: Cast RPDs
Number of subjects: 12
Study 27734089 — intervention group
Group type: EXPERIMENTAL
Intervention: SeLECT Defense™ sealant
Number of subjects: 50
Study 27734089 — intervention group
Group type: COMPARATOR
Intervention: No sealant (control)
Number of subjects: 50
Study 24928639 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 sessions of spinal manipulative therapy (SMT)
Number of subjects: 400
Study 24928639 — intervention group
Group type: COMPARATOR
Intervention: 0 sessions of spinal manipulative therapy (SMT)
Number of subjects: 400
Study 24928639 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 sessions of spinal manipulative therapy (SMT)
Number of subjects: 400
Study 24928639 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 sessions of spinal manipulative therapy (SMT)
Number of subjects: 400
Study 23183149 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingerstick rapid HIV testing
Number of subjects: 1651
Study 23183149 — intervention group
Group type: COMPARATOR
Intervention: Oral fluid rapid HIV testing
Number of subjects: 1651
Study 20550024 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ramelteon
Number of subjects: 14
Study 18568800 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent exposure
Number of subjects: 20
Study 18568800 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 20
Study 17373561 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Treatment (ICBT)
Number of subjects: 66
Study 17373561 — intervention group
Group type: COMPARATOR
Intervention: 12-Step Facilitation Therapy (TSF)
Number of subjects: 66
Study 14619385 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250 mcg/hr after a bolus of 50 mcg)
Number of subjects: 43
Study 14619385 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin (0.4 units/min)
Number of subjects: 43
Study 14619385 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 43
Study 14619385 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 43
Study 14619385 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 10826430 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithotomy position
Number of subjects: 8
Study 10826430 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg positioning
Number of subjects: 8
Study 10826430 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of limbs from stirrups and placing them supine
Number of subjects: 8
Study 8694297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube managed by gravity drainage
Number of subjects: 51
Study 8694297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube managed by continuous low-grade suction
Number of subjects: 51
Study 8694297 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric tube (control)
Number of subjects: 51
Study 1567342 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral‐liked conditioning with 10 acquisition trials
Number of subjects: 0
Study 1567342 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral‐disliked conditioning with increasing acquisition trials
Number of subjects: 0
Study 1567342 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized presentation schedule
Number of subjects: 0
Study 1567342 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockwise presentation schedule
Number of subjects: 0
Study 1567342 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative Style (Feelers vs Thinkers)
Number of subjects: 0
Study 1567342 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency awareness
Number of subjects: 0
Study 3893233 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms once daily
Number of subjects: 20
Study 3893233 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 400 micrograms twice daily
Number of subjects: 20
Study 3893233 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 200 micrograms four times daily
Number of subjects: 20
Study 31664476 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher knowledge scores in women who heard about osteoporosis and had formal education
Number of subjects: 560
Study 31664476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower knowledge scores in women with certain conditions
Number of subjects: 560
Study 29736638 — intervention group
Group type: EXPERIMENTAL
Intervention: Geldart group A
Number of subjects: 4
Study 29736638 — intervention group
Group type: EXPERIMENTAL
Intervention: Geldart group B
Number of subjects: 4
Study 29736638 — intervention group
Group type: EXPERIMENTAL
Intervention: Geldart group C
Number of subjects: 4
Study 29736638 — intervention group
Group type: EXPERIMENTAL
Intervention: Geldart group D
Number of subjects: 4
Study 29736638 — intervention group
Group type: COMPARATOR
Intervention: Sole UV photolysis
Number of subjects: 4
Study 29028696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial pressure plus brain tissue oxygenation monitoring
Number of subjects: 119
Study 29028696 — intervention group
Group type: COMPARATOR
Intervention: Intracranial pressure monitoring alone
Number of subjects: 119
Study 26275650 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week Sun-style Tai Chi (TC) program
Number of subjects: 55
Study 26275650 — intervention group
Group type: COMPARATOR
Intervention: Education program (Control)
Number of subjects: 55
Study 23978451 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed-enriched diet (10% flaxseed)
Number of subjects: 100
Study 23978451 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (control)
Number of subjects: 100
Study 21564519 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhybrid composite (Esthet X; Dentsply/Caulk, Milford, DE, USA)
Number of subjects: 40
Study 21564519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano composite (Ceram X; Dentsply/Caulk)
Number of subjects: 40
Study 21564519 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhybrid composite reinforced with polyethylene fibre - flowable composite unit (Ribbond THM; Ribbond Inc., Seattle, WA, USA; Esthet X flow; Dentsply/Caulk)
Number of subjects: 40
Study 21564519 — intervention group
Group type: COMPARATOR
Intervention: Control group with intact teeth (Group A)
Number of subjects: 40
Study 17907049 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line hormone manipulation
Number of subjects: 65
Study 17907049 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-line hormone manipulation
Number of subjects: 65
Study 16507016 — intervention group
Group type: EXPERIMENTAL
Intervention: Test seekers (141 participants)
Number of subjects: 1600
Study 16507016 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-recruited blood donors (lapsed donors)
Number of subjects: 1600
Study 16507016 — intervention group
Group type: COMPARATOR
Intervention: Accepted donors
Number of subjects: 1600
Study 16507016 — intervention group
Group type: COMPARATOR
Intervention: Rejected donors due to self-reported sexual risk
Number of subjects: 1600
Study 15589870 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy (group 1)
Number of subjects: 100
Study 15589870 — intervention group
Group type: COMPARATOR
Intervention: Fenestration and coagulation (group 2)
Number of subjects: 100
Study 11511714 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pallidotomy
Number of subjects: 32
Study 9313623 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and trandolapril
Number of subjects: 0
Study 9313623 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril
Number of subjects: 0
Study 9313623 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril plus verapamil
Number of subjects: 0
Study 8403792 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous visual analogue scaling of breathlessness during exercise
Number of subjects: 6
Study 8403792 — intervention group
Group type: COMPARATOR
Intervention: Discrete visual analogue scaling of breathlessness during exercise
Number of subjects: 6
Study 3709628 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 21
Study 3709628 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 21
Study 3709628 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 21